162 related articles for article (PubMed ID: 36076499)
1. CCL2 overexpression is associated with paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment.
Yang YI; Wang YY; Ahn JH; Kim BH; Choi JH
Biomed Pharmacother; 2022 Sep; 153():113474. PubMed ID: 36076499
[TBL] [Abstract][Full Text] [Related]
2. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
3. Curcumin Suppresses M2 Macrophage-derived Paclitaxel Chemoresistance through Inhibition of PI3K-AKT/STAT3 Signaling.
Deswal B; Bagchi U; Kapoor S
Anticancer Agents Med Chem; 2024; 24(2):146-156. PubMed ID: 37957871
[TBL] [Abstract][Full Text] [Related]
4. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling.
Han R; Gu S; Zhang Y; Luo A; Jing X; Zhao L; Zhao X; Zhang L
Sci Rep; 2018 Jun; 8(1):9575. PubMed ID: 29934505
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
[TBL] [Abstract][Full Text] [Related]
6. CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.
Fader AN; Rasool N; Vaziri SA; Kozuki T; Faber PW; Elson P; Biscotti CV; Michener CM; Rose PG; Rojas-Espaillat L; Belinson JL; Ganapathi MK; Ganapathi R
Anticancer Res; 2010 Dec; 30(12):4791-8. PubMed ID: 21187454
[TBL] [Abstract][Full Text] [Related]
7. MCP-1/CCL2 Mediated by Autocrine Loop of PDGF-BB Promotes Invasion of Lung Cancer Cell by Recruitment of Macrophages Via CCL2-CCR2 Axis.
Ding M; He SJ; Yang J
J Interferon Cytokine Res; 2019 Apr; 39(4):224-232. PubMed ID: 30730243
[TBL] [Abstract][Full Text] [Related]
8. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
9. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis.
Izhak L; Wildbaum G; Jung S; Stein A; Shaked Y; Karin N
PLoS One; 2012; 7(1):e28305. PubMed ID: 22279523
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
12. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
13. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
14. CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway.
Yasui H; Kajiyama H; Tamauchi S; Suzuki S; Peng Y; Yoshikawa N; Sugiyama M; Nakamura K; Kikkawa F
Clin Exp Metastasis; 2020 Feb; 37(1):145-158. PubMed ID: 31541326
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
[TBL] [Abstract][Full Text] [Related]
16. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
[TBL] [Abstract][Full Text] [Related]
17. CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis.
Raghu H; Lepus CM; Wang Q; Wong HH; Lingampalli N; Oliviero F; Punzi L; Giori NJ; Goodman SB; Chu CR; Sokolove JB; Robinson WH
Ann Rheum Dis; 2017 May; 76(5):914-922. PubMed ID: 27965260
[TBL] [Abstract][Full Text] [Related]
18. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
19. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile.
Sierra-Filardi E; Nieto C; Domínguez-Soto A; Barroso R; Sánchez-Mateos P; Puig-Kroger A; López-Bravo M; Joven J; Ardavín C; Rodríguez-Fernández JL; Sánchez-Torres C; Mellado M; Corbí AL
J Immunol; 2014 Apr; 192(8):3858-67. PubMed ID: 24639350
[TBL] [Abstract][Full Text] [Related]
20. MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.
Zhang LY; Yu JY; Leng YL; Zhu RR; Liu HX; Wang XY; Yang TT; Guo YN; Tang JL; Zhang XC
Cancer Gene Ther; 2022 Jun; 29(6):770-783. PubMed ID: 34145425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
